RxDoctor Payments Data

Thomas Sperry, MD

Cardiovascular Disease · Arlington, TXNPI 1578977856

Payments from drug & device makers

$2,717in general payments, 2019–2025

Across 138 payments — averaging $19.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$640
  • Novartis$336
  • Abbott$321
  • Pfizer$311
  • Johnson & Johnson$204
  • E.r. Squibb & Sons, L.L.C.$140
  • plus $766 from 16 others

What the payments were for

  • Food & beverage$2,717100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,717 in reported general payments places this provider in the 40th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$275,274
Medicare patients
609
Services billed
2,879

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban639$770,901
JardianceEmpagliflozin236$286,745
XareltoRivaroxaban220$271,912
EntrestoSacubitril/Valsartan125$130,265
Repatha SureclickEvolocumab87$92,947
MultaqDronedarone Hcl21$29,536
BrilintaTicagrelor16$13,711
Metoprolol Succinate771$10,519
Praluent PenAlirocumab11$6,486
Rosuvastatin Calcium423$6,266
Carvedilol571$5,684
Atorvastatin Calcium546$5,590
Ranolazine ErRanolazine41$4,347
Flecainide Acetate71$3,763
Ezetimibe214$3,568

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$311$770,901639 claims
Boehringer IngelheimJardiance$640$286,745236 claims
Johnson & JohnsonXarelto$204$271,912220 claims
NovartisEntresto$336$130,265125 claims
Sanofi-aventis U.S. LLCMultaq$16$29,53621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →